Shimizu T, Usuda N, Yamanda T, Sugenoya A, Iida F
Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Cancer. 1993 May 1;71(9):2807-12. doi: 10.1002/1097-0142(19930501)71:9<2807::aid-cncr2820710920>3.0.co;2-5.
To clarify the proliferative activity of human thyroid tumors, the labeling index of various thyroid tumors was evaluated by proliferating cell nuclear antigen (PCNA)/cyclin immunostaining.
Surgically removed thyroid carcinoma, adenoma, adenomatous goiter, normal thyroid, and breast carcinoma were used for the study. Small pieces of tissue from the surgical materials were fixed in Methacarn solution (methanol-chloroform-acetic acid = 6:3:1) (Wako junyaku Co., Osaka, Japan) and embedded in paraffin. Sections were stained with PCNA/cyclin monoclonal antibody.
The reaction product for PCNA/cyclin was observed mainly on nuclei. The ratio of the PCNA/cyclin-positive nuclei to the total number of nuclei was compared among the tumors. Ratios of PCNA/cyclin-positive nuclei were 4.9% in well-differentiated papillary carcinoma of the thyroid, 4.6% in poorly differentiated papillary carcinoma of the thyroid, 3.6% in thyroid follicular carcinoma, 1.9% in adenomatous goiter, 2.0% in thyroid follicular adenoma, and 0.6% in normal thyroid tissues.
It was shown in this study that the ratio of PCNA/cyclin-positive nuclei reflects the relative clinical behavior of thyroid tumors.
为阐明人类甲状腺肿瘤的增殖活性,通过增殖细胞核抗原(PCNA)/细胞周期蛋白免疫染色评估了各种甲状腺肿瘤的标记指数。
将手术切除的甲状腺癌、腺瘤、腺瘤性甲状腺肿、正常甲状腺组织及乳腺癌组织用于本研究。手术取材的小块组织用Methacarn固定液(甲醇 - 氯仿 - 乙酸 = 6:3:1)(日本大阪和光纯药株式会社)固定后石蜡包埋。切片用PCNA/细胞周期蛋白单克隆抗体染色。
PCNA/细胞周期蛋白的反应产物主要见于细胞核。比较了各肿瘤中PCNA/细胞周期蛋白阳性细胞核与细胞核总数的比例。甲状腺高分化乳头状癌中PCNA/细胞周期蛋白阳性细胞核的比例为4.9%,甲状腺低分化乳头状癌中为4.6%,甲状腺滤泡癌中为3.6%,腺瘤性甲状腺肿中为1.9%,甲状腺滤泡性腺瘤中为2.0%,正常甲状腺组织中为0.6%。
本研究显示PCNA/细胞周期蛋白阳性细胞核的比例反映了甲状腺肿瘤的相对临床行为。